BST2/Tetherin Inhibits Dengue Virus Release from Human Hepatoma Cells

Xiao-Ben Pan1*, Jin-Chao Han1, Xu Cong1, Lai Wei1,2*

1 Peking University People’s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing, P.R. China, 2 Peking University People’s Hospital, Department of Infectious Disease, Beijing, P.R. China

Abstract

Type I interferons (IFN) have been shown to play an important role for inhibiting Dengue virus (DENV) infection. Identifying IFN-induced cellular proteins are essential for understanding its mechanisms against DENV. Here we established stable Huh7-derived cell lines expressing the IFN-induced cell membrane protein BST2 (Huh7-BST2) or its variant bearing a V5 tag at the C-terminal (Huh7-BST5CV5). These cell lines were infected with DENV to determine proteins modulating their anti-DENV response. We found that expression of BST2 did not affect the efficiency of DENV infection and intracellular replication. Rather, it significantly reduced the virion yield of the infected cells, particularly at low MOI infection. In addition, BST2 also decreased the foci formation and the size of infectious foci in cultured Huh7 monolayers with media containing methocellulose. The addition of the V5 tag at C-terminal inhibited the GPI modification of BST2 and blocked its shift from endoplasm to cytoplasmic membrane. BST2CV5 did not affect DENV infection and foci formation in Huh7 cells but reduced virion yield by 1 log at low MOI infection. Interestingly, intracellular BST2CV5 expression was reduced by high level of DENV production.

Conclusion: Our results imply that BST2 is a functional mediator of the IFN response against DENV infection. BST2 inhibits the release of DENV virions from Huh7 cells and limits viral cell-to-cell transmission. BST2CV5 variant is unable to inhibit DENV release but impairs viral infection in cells.

Citation: Pan X-B, Han J-C, Cong X, Wei L (2012) BST2/Tetherin Inhibits Dengue Virus Release from Human Hepatoma Cells. PLoS ONE 7(12): e51033. doi:10.1371/journal.pone.0051033

Copyright: © 2012 Pan et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by National Natural Science Foundation of China (30972605 and 30700697) and Program for New Century Excellent Talents in University (NCET, BMU20110272). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: Pansxboben@pkuph.edu.cn (XP); weilai@pkuph.edu.cn (LW)

Introduction

Dengue virus (DENV) belongs to the family Flaviviridae, and DENV infection remains a global public health problem due to a lack of effective treatment or vaccine [1–3]. The World Health Organization estimates that at least 2.5 billion people are at risk of contracting dengue and the number of infectious worldwide may reach 10 million cases per year [4]. Most infected patients experience dengue fever, but 2 to 20% of all cases manifest as dengue hemorrhagic fever, a severe and often lethal illness [5].

Although, DENV has been demonstrated to inhibit interferon (IFN) signaling in cells, this inhibition is attributed to several DENV proteins and pre-existing enhancing antibodies [6–8]. Type I IFN plays an important role in the pathogenesis of DENV infection. Mice with deficiencies in the type I IFNs production or Type I IFN signaling in cells, this inhibition is attributed to several DENV proteins and pre-existing enhancing antibodies [6–8]. Type I IFN signaling pathway are susceptible to DENV infection [9–11]. Clinically, low levels of the IFN-α/β producing plasmacytoid dendritic cells have been observed in dengue hemorrhagic fever patients [12,13]. Secretion of type I interferon by dendritic cells and mast cells contributes to the generation of antiviral innate and adaptive immune responses [14–16].

IFNs can alter the expression of hundreds of cellular genes [17]. Our group and others have previously demonstrated that the expression of IFN-inducible proteins, such as Viperin, IFITM2, IFITM3, double stranded RNA dependent protein kinase (PKR), and interferon-stimulated gene (ISG)-20, in HEK293 cells was able to inhibit DENV [18–21]. Most recently, ISG15 was demonstrated to play an anti-DENV function via protein ISGylation. ISG12b2 was identified as a novel inner mitochondrial membrane ISG that regulates mitochondria-mediated apoptosis during DENV infection [22,23]. In our current study, we report that the expression of ISG BST2 (bone marrow stromal cell antigen 2), also known as CD317, HM1.24 or tetherin [24–26], plays a role in inhibiting DENV production.

Materials and Methods

Plasmid construction and establishment of cell lines

Plasmid pcDNA3/FRT/BST2 was constructed as described previously [22]. To construct plasmid pcDNA5/FRT/BST2CV5, BST2 cDNA (Gene ID: 684) was amplified from pcDNA5/FRT/BST2 with a pair of primers (Forward: 5’-GAGCTTAAAGATGGATCTACGTCTGATGACTA-3’; Reverse: 5’-CACGCGGCCGCCCTGCAGCGCAGCGCTGAGGCCC-3’). The PCR product was digested with All II and Not I (New England Biolabs, Ipswich, MA, USA), and ligated with vector fragment recovered from All II and Not I digested pcDNA5/FRT/Viperin-CV5 [27]. To establish stable Huh7 cell lines that express BST2 (Huh7-BST2) and carboxyl-terminally V5 tagged BST2 (Huh7-BST5CV5), Huh7 cells (Institute of Cytology, Chinese Academy of Sciences, Shanghai, China) were transfected with plasmid...
**Expression levels of BST2 and its variant in the cell lines**

Expression levels of BST2 and its variant in the cell lines were evaluated using western blot by comparing parental Huh7 cells treated with 0 to 3000 IU/ml of IFN-α for 48 h. Whole cell monolayers were washed once with phosphate-buffered saline buffer and lysed with 1× detergent and cytosol fractions were separated by centrifugation methods by using of a subcellular protein fractionation kit (Thermo Scientific, Rockford, IL). A fraction of the cell lysate was separated on sodium dodecyl sulfate 12% SDS polyacrylamide gels and electrophoretically transferred onto a polyvinylidene difluoride membrane (PVDF, EMD Millipore). The proteins on membrane were bound with indicated antibodies and detected by Odyssey Infrared Imaging System (LI-COR Biotechnology, Lincoln, NE).

**Determination of infectivity titer**

Infectivity titers were determined by using an earlier described protocol [29]. Naive Huh7 cells (2×10⁵) were plated per well in a 96-well plate the day before inoculation with 10-fold dilutions of cell culture supernatants in replicates of six for 2 days. Primary antibody for development was anti-DENV E protein (1:500 dilution, Clone D1-4G2-4-15, EMD Millipore). Wells were scored positive if one or more cells were infected, and the TCID50 value was calculated. The experiment was performed in 3 replicates to generate statistically sufficient data.

**Results**

Expression and localization of BST2 and BST2CV5 in Huh7 cells

Huh7 is a hepatocarcinoma cell line, which is highly permissive for DENV infection [30]. We established Huh7-derived stable cell lines that express wild-type or carboxy-terminally V5 epitope-tagged mutant BST2 proteins, designated as Huh7-BST2 and Huh7-BST2CV5, respectively. As shown in Fig. 1, expression of BST2 and its variant in the two cell lines were confirmed by indirect immunofluorescent staining and western blot. Consistent with a previous report [26], wild-type BST2 was observed in cells with or without detergent-permeabilizing treatment. This suggests that BST2 localizes both in the cytoplasm and plasma membrane. In marked contrast, the C-terminal V5-tagged BST2 protein (BST2CV5) was only observed in the presence of detergent-permeabilizing treatment and mostly detected in cytoplasm (Fig. 1A and C). This suggests that the addition of 14 amino acid residues of V5 epitope tag at the C-terminus of BST2 alters the intracellular trafficking of BST2 that prevents its expression on the cell surface. To evaluate the expression levels of BST2 and its variant in the cell lines, we compared their expression levels with that of parent Huh7 induced by various concentrations of IFN-α.

The results showed that the expression of BST2 and BST2CV5 in cell lines was comparable to that of 100–300 U/ml IFN-α induction (Fig. 1B).

**BST2 inhibits dengue infection at a post entry step**

To test the effects of BST2 expression on DENV infection, parental Huh7, Huh7-BST2 and Huh7-BST2CV5 cells were infected with DENV at an MOI of 0.01 (Low) and 10 (High). While DENV infection was observed in the majority of parental
Huh7 cells at low MOI infection on day 2, only a small fraction of Huh7-BST2 cells were infected (Fig. 2A). Using supernatant, DENV infectivity decreased by about 2 logs suggesting that at least one step of DENV replication cycle is inhibited in Huh7-BST2 cells (Fig. 3). Compared to wild-type BST2, expression of BST2CV5 demonstrated a weaker but still significant antiviral effect against DENV.

A high MOI (10) infection assay was performed to determine whether BST2 inhibits DENV entry in the cells. According to Poisson distribution, cells infected with DENV than one virus is calculated by formula \( P(>1) = 1 - e^{-10}(10+1) = 0.995 \). Therefore, such a multiplicity of infection will ensure that nearly 100% of the cells are initially infected with at least one infectious DENV virion. As shown in Fig. 2B, expression of BST2 and BST2CV5 did not inhibit DENV infection at high MOI. Interestingly, high MOI infection of DENV decreased the expression of BST2CV5 but not BST2. BST2 expression was able to decrease supernatant viral infectivity by about 25%, whereas no changes in intracellular viral infectivity were observed in the Huh7-BST2CV5 and parental Huh7 cells (Fig. 3).

BST2 does not inhibit DENV replication

Infectious foci count and In-cell western blots were used to obtain an overall assessment of DENV spread and infection in these cell lines. In the foci count, free virus transmission is limited by 0.5% methocellulose in the medium. Among these three cell lines at high MOI infection, no obvious difference was observed in the intracellular DENV 4G2 protein and viral RNA levels (Fig. 4). This observation implied that BST2 and its variant did not inhibit DENV viral entry, viral replication, and protein translation.

While DENV was freely transmitted in the infection system without restriction of 0.5% methocellulose, intracellular 4G2 protein markedly increased in all three cell lines at high MOI infection, whereas BST2 still moderately inhibited viral replication in Huh7-BST2 cells (Fig. 5). These results suggest that multiple rounds of infection from progeny virions occurred in this free transmission system that was partially inhibited by BST2.

BST2 inhibits virion release and cell-to-cell transmission

The low MOI infection plot, as shown in Fig. 4A, shows the representative DENV-infected cell foci from the cultures of the three cell lines. The quantitative analysis showed that the
infectious foci per well were decreased to about 30% by BST2 (Fig. 4B). However, BST2CV5 did not exert any effect. The average DENV-positive cell number per foci is 238 in Huh7 cells, whereas the cell numbers in the Huh7-BST2 and Huh7-BST2CV5 cell foci were 78 and 175, respectively. Altogether, the expression of BST2 but not BSTCV5 inhibited DENV release and cell-to-cell transmission in Huh7 cells.

Discussion

BST2 is a transmembrane protein that contains a short N-terminal cytoplasmic domain, a membrane-spanning alpha-helix, a coiled-coil ectodomain, and a C-terminal GPI anchor [31]. This antiviral protein localizes at the plasma membrane as well as the membranes of multiple intracellular vesicles, including endosomes and the trans-Golgi network [32,33]. At the plasma membrane, BST2 is found within cholesterol-enriched lipid rafts, presumably due to its C-terminal GPI modification. This optimally positions BST2 to interfere directly with virion release, since several lipid-enveloped viruses, including HIV-1 and Ebola, bud selectively from raft domains [34–38]. Consistent with these reports, our results showed that BST2 localizes to both the cell membrane and cytoplasm. The addition of the V5 tag at the C-terminus of BST2 demonstrated an altered intracellular distribution (Fig. 1). Furthermore, similar as previous report [25,39], we found that three bands of BST2 distributed in the range from 30 to 36kd by western blot. We supposed that the different level of modification of BST2 likely cause the different size of BST2. However, for
Figure 4. BST2 inhibits DENV spread via cell-to-cell transmission. The cells were infected with DENV at a MOI of 0.01 or 10 for 1 h and culture media were replaced with media containing 0.5% methocellulose to prevent cell-free virus infection and cultured for 2 days. (A) Representative DENV-infected cell foci from cultures of the three cell lines. The infected cell foci and cell viability were revealed by In-Cell Western assay by using antibody against DENV E protein and Sapphire 700 staining, respectively. The indicated gray values of the dots were quantified by using of an Odyssey Infrared Imaging System (LI-COR Biotechnology). (B) The average infectious foci number per well in 24-well plate and the average DENV-infected cell number per focus from 100 foci were plotted. (C) The intracellular DENV RNA was determined for the cells infected with DENV at MOI of 10 by qRT-PCR assay. The values were presented as percentage of values from the Huh7-BST2 and Huh7-BST2CV5 cells compared with that from parent Huh7 cells. The experiment was performed in 3 replicates to generate statistically sufficient data. p values were calculated using Student’s t test.
doi:10.1371/journal.pone.0051033.g004

Figure 5. In-cell western analysis for DENV infection in Huh7-BST2 and Huh7-BST2CV5 cells. Cells were infected with DENV at indicated MOI and cultured for 2 days with complete medium. Cells were fixed and double-staining of DENV 4G2 protein and BST2 were revealed by In-Cell western assay. The indicated gray values of the dots were quantified by using of an Odyssey Infrared Imaging System (LI-COR Biotechnology). The values represent average from 3 independent experiments.
doi:10.1371/journal.pone.0051033.g005
BST2V5, a single band of BST2 was observed and subcellular distribution of BST2 was changed. These results suggests that the addition of 14 amino acid residues of V5 epitope at the C-terminus prevents modification of the GPI anchor.

BST2 potently inhibits the release of many enveloped viruses, including all retroviruses as well as members from five other families, including Filoviridae (Ebola and Marburg viruses), Arenaviridae (Lassa fever virus), Herpesviridae (Kaposi’s sarcoma-associated herpesvirus) and Rabdoviridae (Vesicular stomatitis virus) and Flaviviridae (Hepatitis C virus) [26,40–44]. It has been shown that BST2 tethers buddning virions on the cell surface, which are subsequently endocytosed and degraded in the lysosomes [26]. BST2 can inhibit cell-to-cell transmission of HIV [45,46]. However, interestingly, recent report also showed that BST2 enhanced HCMV entry into monocytic TPH-1 cells. This might promote cell-to-cell transfer of HIV under some circumstances [47,48]. In this study, we demonstrate that BST2 expression did not effect viral replication and entry in Huh7 cells at high MOI infection (Fig. 2B and Fig. 4). However, supernatant viral infectivity detection showed that BST2 inhibited DENV production (Fig. 3). Infectious foci assays strongly implied that BST2 expression markedly inhibits mature virions budding and cell-to-cell transmission (Fig. 4).

The addition of the V5 tag at the C-terminus of BST2 altered its intracellular distribution (Fig. 1). This suggests that the addition of the V5 tag likely impede C-terminal GPI anchor modification that is responsible for its enrichment in lipid rafts [25]. Although it demonstrated a weak antiviral activity in comparison with wild-type BST2, BST2CV5 was still able to inhibit DENV replication (Fig. 2A, Fig. 3 and Fig. 5). Similar to BST2, BST2CV5 expression did not effect DENV RNA replication and viral entry. However, unlike BST2, BST2CV5 did not inhibit foci formation at low MOI infection (Fig. 4). This observation suggested that BST2CV3 was not able to inhibit cell-to-cell transmission of DENV in Huh7 cells. Furthermore, both immunofluorescence staining and In-cell western blot analysis showed high levels of DENV replication in Huh7 cells decrease the levels of intracellular BST2CV5, but not BST2 (Fig. 2B and Fig. 5). High DENV production decreased intracellular BST2CV5 levels supports our proposed hypothesis that BST2CV5 likely incorporates into DENV virion and excretes via virus budding [32]. Owing to the direct interaction between BST2 and the virion [49–51], this observation also suggests that sufficient amount of BST2 is indispensable to efficiently tether virus, especially a high yield virus like DENV. Indeed, this observation also addresses the issue whether a physiological induction of BST2 is sufficient and effective to inhibit DENV release in vivo.

In summary, although the additional studies are needed to explore the detailed mechanism, our results demonstrate that BST2 is an integral part of the host innate defense components against DENV infection in Huh7 cells.

Acknowledgments

We thank Dr. Ju-tao Guo and Matt Campagna from Drexel University for critical reading of the manuscript.

Author Contributions

Conceived and designed the experiments: XP LW. Performed the experiments: XP JH. Analyzed the data: XP LW. Contributed reagents/materials/analysis tools: JH XC. Wrote the paper: XP.

References

1. Lambrechts L, Scott TW, Gubler DJ (2010) Consequences of the expanding global distribution of Aedes albopictus for dengue virus transmission. PLoS Negl Trop Dis 4: e646.
2. Thomas SJ, Eddy TP (2011) Vaccines for the prevention of dengue: Development update. Hum Vaccin 7: 674-684.
3. WHO-VMI Dengue Vaccine Modeling Group, Beatty M, Boni MF, Brown S, Forrest S, et al. (2012) Modeling prospects for future dengue vaccines. Vaccine 30: 3569-3579.
4. WHO websit. Available: http://www.who.int/mediacentre/factsheets/fs117/. Accessed 2012 Jan.
5. Guzmán MG, Kouri G (2002) Dengue: an update. Lancet Infect Dis 2: 33–42.
6. Rodriguez-Madrez JR, Bernal-Rubio D, Kaminski D, Boyd K, Fernandez-Sesma A (2010) Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J Virol 84: 4845–4850.
7. Mazzon M, Jones M, Davidson A, Chain B, Jacobs M (2009) Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal transducer and activator of transcription 2 phosphorylation. J Infect Dis 200: 1261–1270.
8. Moorthy N, Kalayanarooj S, Udom S (2010) Subversion of innate defenses by the interplay between DENV and pre-existing enhancing antibodies: TLRs signaling collapse. PLoS Negl Trop Dis 4: e924.
9. Perry ST, Buck MD, Lada SM, Schindler C, Shresta S (2011) STAT2 mediates interferon-induced cellular responses to the dengue virus genome in human dendritic cells. J Virol 85: 8276-8291.
10. Perry ST, Buck MD, Lada SM, Schindler C, Shresta S (2011) STAT2 mediates innate immunity to Dengue virus in the absence of STAT1 via the type I interferon receptor. PLoS Pathog 7: e1001297.
11. Liang Z, Wu S, Li Y, He L, Wu M, et al. (2011) Activation of Toll-like receptor 3 impairs the dengue virus serotype 2 replication through induction of IFN-β in cultured hepatoma cells. PLoS One 6: e23356.
12. Breccqant P, Wasiakur N, Nkoghe D, Ndjooyi-Mbigumou A, Padilla C, et al. (2010) Acute dengue virus infection in Gabonese patients is associated with an early innate immune response, including strong interferon alpha production. BMC Infect Dis 10: 356.
13. Pichyangkul S, Eddy TP, Kalayanarooj S, Nialaal A, Yongvanitchit K, et al. (2003) A blunted blood plasma cytokind dendritic cell response to an acute systemic viral infection is associated with increased disease severity. J Immunol 171: 5571–5578.
14. Le Bon A, Tough DF (2002) Tough. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 14: 432–436.
15. St John AL, Rathore AP, Yap H, Ng ML, Metcalfe DD, et al. (2011) immune surveillance by mast cells during dengue infection promotes natural killer (NK) and NKT-cell recruitment and viral clearance. Proc Natl Acad Sci U S A 108: 9190–9195.
16. de-Oliveira-Pinto LM, Marinho CF, Povas TF, de Azereedo EL, de Souza LA, et al. (2012) Regulation of inflammatory chemokine receptors on blood T cells associated to the circulating versus liver chemokines in dengue Fever. PLoS One 7: e36527.
17. Stenson DR, Medzhitov R (2006) Type I interferons in host defense. Immunity 25: 373–381.
18. Der SD, Zhou A, Williams BR, Silverman RH (1998) Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 95: 15623–15628.
19. Fink J, Gu F, Ling I, Tolkenstam T, Olfat F, et al. (2007) Host gene expression profiling of dengue virus infection in cell lines and patients. PLoS Negl Trop Dis 1: e66.
20. Jiang D, Weidner JM, Qing M, Pan XR, Guo H, et al. (2010) Identification of five interferon-induced cellular proteins that inhibit west nile virus and dengue virus infections. J Virol 84: 8332–8341.
21. Brass AL, Huang JC, Benyta V, John SP, Krishnan MN, et al. (2009) The HFTM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139: 1243–1254.
22. Lu MY, Liao F (2011) Interferon-stimulated gene ISG15α is localized to the inner mitochondrial membrane and mediates virus-induced cell death. Cell Death Differ 18: 925–936.
23. Dai J, Pan W, Wang P (2011) ISG15 facilitates cellular antiviral response to dengue and west nile virus infection in vitro. Virol J 8: 468.
24. Goto T, Kennel SJ, Abe M, Takahata M, Kosaka M, et al. (1996) A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 84: 1922–1930.
25. Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G (2007) Clathrin-mediated endocytosis of a lipid raft-associated protein is mediated through a dual tyrosine motif. J Cell Sci 120: 3530–3538.
26. Neij SJ, Zang T, Bienzlasz PD (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425–430.
27. Jiang D, Guo H, Xu C, Chang J, Gu B, et al. (2008) Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 82: 1665–1678.
28. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG (2007) A dengue fever viremia model in mice shows reduction in viral replication and suppression of
the inflammatory response after treatment with antiviral drugs. J Infect Dis 195: 665–674.

29. Wang QY, Patel SJ, Vangrevelinghe E, Xu HY, Rao R, et al. (2009) A small-molecule dengue virus entry inhibitor. Antimicrob Agents Chemother 53: 1823–1831.

30. Ang F, Wong AP, Ng MM, Clau JJ (2010) Small interference RNA profiling reveals the essential role of human membrane trafficking genes in mediating the infectious entry of dengue virus. Virol J 7: 24.

31. Rollason R, Korolchuk V, Hamilton C, Jepson M, Bunting G (2009) A CD417/tetherin-RICH2 complex plays a critical role in the organization of the subapical actin cytoskeleton in polarized epithelial cells. J Cell Biol 184: 721–736.

32. Kuping S, Korolchuk V, Rollason R, Sugden A, Wilde A, et al. (2003) Bat-2/tHM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4: 694–709.

33. Dube M, Roy BB, Guiot-Guillain P, Mercier J, Binette J, et al. (2009) Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol 83: 4574–90.

34. Nguyen DH, Hildreth JE (2000) Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 74: 3264–3272.

35. Panchal RG, Ruthel G, Kenny TA, Kallstrom GH, Lane D, et al. (2009) Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network. J Virol 83: 4574–90.

36. Hinz A, Miguet N, Natrajan G, Usami Y, Yamanaka H, et al. (2010) Structural basis of HIV-1 tethering to membranes by the BST-2/tetherin ectodomain. Cell Host Microbe 7: 314–323.

37. Hammonds J, Ding L, Chu H, Geller K, Robbins A, et al. (2012) The tetherin/BST-2-coiled-coil ectodomain mediates plasma membrane microdomain localization and restriction of particle release. J Virol 86: 2259–2272.

38. Barrett BS, Smith DS, Li SX, Guo K, Hasenkrag RJ, et al. (2012) A single nucleotide polymorphism in tetherin promotes retrovirus restriction in vivo. PLoS Pathog 8: e1002956.

39. Ruiz A, Lau D, Mitchell RS, Hill MS, Schmitt K, Guatelli JC, Stephens EB (2010) BST-2 mediated restriction of simian-human immunodeficiency virus. Virology 406: 312–21.